A large, research-based bio-pharmaceutical company partnered with BIOVIA in a pilot program to identify lead drug candidates faster.
Learn how the customer leveraged BIOVIA's AI-driven ideation tool, Generative Therapeutics Design (GTD) on 3DEXPERIENCE® Platform to:
-
Incorporate 3D information for protein-ligand interactions to improve AI and ML models for small molecule drug design
-
Re-identify lead compounds in clinical development within months, along with 41 closely related compounds
-
Generate additional, novel chemical compounds that are slated for future testing